TRAF2 and neoplasm: First, Litchfield et al.76 analyzed genomic data of up to 1000 ICB-treated patient samples collected from 12 published cohorts across 7 tumor types, and showed that copy number loss of TRAF2 is associated with response and CCND1 amplification is associated with resistance.